# JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

> **NCT06514768** · EARLY_PHASE1 · RECRUITING · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 20 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia (B-ALL)

## Interventions

- **BIOLOGICAL:** JY231

## Key facts

- **NCT ID:** NCT06514768
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06514768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06514768, "JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06514768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*